USFDA Approves Alembic Pharma Five Products In Over A Month
Mumbai: Alembic Pharmaceuticals Limited announced today that it has received US Food & Drug Administration (USFDA) approvals on five of its products. The company has received five product approvals – three final and two tentative – from 1st April 2024 till 8th May 2024.
This includes Diazepam Injection USP, 10 mg/2 mL (5 mg/mL), Single-Dose Prefilled Syringe, Selexipag Tablets 1,000 mcg and 1,200 mcg, Binimetinib, Tretinoin Cream USP, 0.1%, and Clindamycin Phosphate Topical Gel USP 1%.
Diazepam Injection USP, 10 mg/2 mL (5 mg/mL), Single-Dose Prefilled Syringe, final approval, of Hoffmann LA Roche Inc with brand name, Valium (Diazepam) Injection, is indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety.
Selexipag Tablets 1,000 mcg and 1,200 mcg, tentative approval, of Actelion Pharmaceuticals Inc. with brand name, Uptravi, is indicated for the treatment of pulmonary arterial hypertension (PAH, WHO Group I) to delay disease progression and reduce the risk of hospitalisation for PAH.
Binimetinib, tentative approval, of Array Biopharm with brand name, Mektovi, is a kinase inhibitor indicated, in combination with encorafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation.
Tretinoin Cream USP, 0.1%, final approval, of Bausch Health US, LLC., USA with brand name, Retin-A, is indicated for topical application in the treatment of acne vulgaris.
Clindamycin Phosphate Topical Gel USP 1%, final approval, of Pharmacia & Upjohn with brand name, Cleocin T, is indicated in the treatment of acne vulgaris.
Alembic has a cumulative total of 201 ANDA approvals (173 final approvals and 28 tentative approvals) from USFDA.
Headquartered in India, Alembic Pharmaceuticals Limited is a vertically integrated research and development pharmaceutical company. It is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world. Alembic's state of the art research and manufacturing facilities are approved by regulatory authorities of many developed countries including the USFDA.
Read also: Alembic Pharma gets tentative USFDA nod for breast cancer drug Ribociclib in March Quarter
Disclaimer: This website is designed for healthcare professionals and serves solely for informational purposes.
The content provided should not be interpreted as medical advice, diagnosis, treatment recommendations, prescriptions, or endorsements of specific medical practices. It is not a replacement for professional medical consultation or the expertise of a licensed healthcare provider.
Given the ever-evolving nature of medical science, we strive to keep our information accurate and up to date. However, we do not guarantee the completeness or accuracy of the content.
If you come across any inconsistencies, please reach out to us at
admin@doctornewsdaily.com.
We do not support or endorse medical opinions, treatments, or recommendations that contradict the advice of qualified healthcare professionals.
By using this website, you agree to our
Terms of Use,
Privacy Policy, and
Advertisement Policy.
For further details, please review our
Full Disclaimer.
0 Comments
Post a comment
No comments yet. Be the first to comment!